Gennex Laboratories Limited (BOM:531739)

Market Cap	2.86B -0.5%
Revenue (ttm)	1.52B +16.0%
Net Income	191.43M +1.6%
EPS	0.75 -1.4%
Shares Out	242.95M
PE Ratio	15.76
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	618,544
Open	12.02
Previous Close	12.11
Day's Range	11.60 - 12.39
52-Week Range	7.05 - 17.25
Beta	0.77
Analysts	n/a
Price Target	n/a
Earnings Date	May 30, 2026

About Gennex Laboratories

Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase ...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 115
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531739

Financial Performance

In fiscal year 2025, Gennex Laboratories's revenue was 1.38 billion, an increase of 59.03% compared to the previous year's 867.14 million. Earnings were 181.23 million, an increase of 37.55%.